Sodium Polystyrene Sulfonate Suspension
NDC 35573-108
Product Information
Sodium Polystyrene Sulfonate is a ANDA-approved product labeled by Burel Pharmaceuticals, Llc. This medication is used to treat a high level of potassium in your blood. It is supplied as a brown suspension for oral; rectal administration. This product entry covers the primary NDC 35573-108 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
- Oral - Administration to or by way of the mouth.
- Rectal - Administration to the rectum.
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
Code Structure Chart
Product Details
What is NDC 35573-108?
What are the uses of this product?
What are Active Ingredients of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- SODIUM POLYSTYRENE SULFONATE (UNII: 1699G8679Z)
- POLYSTYRENE SULFONIC ACID (UNII: 70KO0R01RY) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- WATER (UNII: 059QF0KO0R)
- PROPYLENE GLYCOL (UNII: 6DC9Q167V3)
- SACCHARIN SODIUM (UNII: SB8ZUX40TY)
- METHYLPARABEN (UNII: A2I8C7HI9T)
- PROPYLPARABEN (UNII: Z8IX2SC1OH)
- XANTHAN GUM (UNII: TTV12P4NEE)
- ANHYDROUS CITRIC ACID (UNII: XF417D3PSL)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 313072 - sodium polystyrene sulfonate 15 GM in 60 mL Oral or Rectal Suspension
- RxCUI: 313072 - sodium polystyrene sulfonate 250 MG/ML Oral Suspension
- RxCUI: 313072 - sodium polystyrene sulfonate 15 GM per 60 ML Oral Suspension
- RxCUI: 313072 - sodium polystyrene sulfonate 30 GM per 120 ML Oral Suspension
* Please review the full disclaimer at the bottom of this page.